trending Market Intelligence /marketintelligence/en/news-insights/trending/8xEt97CfNH5bRjSmcxz3xA2 content esgSubNav
In This List

Vanda Pharmaceuticals jet lag drug accepted for US FDA review

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Vanda Pharmaceuticals jet lag drug accepted for US FDA review

Vanda Pharmaceuticals Inc.'s jet lag disorder drug Hetlioz has been accepted by the U.S. Food and Drug Administration for review.

The agency has set a date of Aug. 16, 2019, for completing its review, according to Vanda's Dec. 20 press release.

Hetlioz is already approved for treating non-24 hour sleep-wake disorder and is in clinical trials for symptoms of a rare disorder called Smith-Magenis syndrome.

Washington, D.C.-based Vanda is a biopharmaceutical company that develops products to treat central nervous system disorders.